Standards, Options and Recommendations for the management of prostate cancer: Therapeutic decision criteria;Standards, Options et Recommandations 2001 pour la prise en charge des patients atteints de cancer de la prostate non métastatique: Éléments de la décision thérapeutique

Bulletin du Cancer

Volumn 89, Issue 6, 2002, Pages 619-634

  Villers, Arnauld ^a   Pabot Du Chatelard, Pierre ^a   Pommier, Pascal ^a   Soulié, Michel ^a   Bataillard, Anne ^a   Fervers, Béatrice ^a   Bachaud, Jean Marc ^a   Berger, Nicole ^a   Bertrand, Anne Françoise ^a   Bouvier, Raymonde ^a   Brune, Daniel ^a   Daver, Alain ^a   Fontaine, Éric ^a   Hajllot, Olivier ^a   Lagrange, Jean Léon ^a   Molinié, Vincent ^a   Muratet, Jean Pierre ^a   Peneau, Michel ^a   Prapotnich, Dominique ^a   Ravery, Vincent ^a   Richaud, Pierre ^a   Rossi, Dominique ^a   more..

^a FNCLCC   (France)

Author keywords

Adult; Clinical practice guidelines; Prognosis factor; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; CANCER DIAGNOSIS; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL PRACTICE; CONCENTRATION RESPONSE; DISEASE COURSE; FOLLOW UP; HEALTH CARE QUALITY; HUMAN; MEDICAL DECISION MAKING; MEDICAL SPECIALIST; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; REVIEW; STANDARD; VALIDATION PROCESS;

BIOPSY; DISEASE PROGRESSION; HUMANS; LIFE EXPECTANCY; MALE; MORBIDITY; NEOPLASM METASTASIS; POSTOPERATIVE PERIOD; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY; TREATMENT OUTCOME;

EID: 0036073960     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Méthodologie de développement des standards, options et recommandations diagnostiques et thérapeutiques en cancérologie
2. SOR: Project methodology
3. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease
4. Prostate cancer screening (III): Risk factors, natural history, course without treatment: Characteristics of detected cancers
5. Unsuspected adenocarcinomna of the prostate in patients undergoing cystoprostatectomny for other causes: Incidence, histology and morphometric observations
6. Early detection of prostate cancer
7. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage Tlc) prostate cancer
8. Observations on the doubling time of prostate cancer: The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume
9. Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate
10. Core cancer length in ultrasound-guided systematic sextant biopsies: A preoperative evaluation of prostate cancer volume
11. De-differentiation with time in prostate cancer and the influence of treatment on the course of the disease
12. Origin and development of carcinoma in the prostate
13. Patterns of progression in prostate cancer
14. Veterans Administration Cooperative Urological Research Group: Histological grading and clinical staging of prostatic carcinoma
15. Biological determinants of cancer progression in men with prostate cancer
16. Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: Epidemiologic significance of annual changes
17. Recent results of management of palpable clinically localized prostate cancer
18. Long-term survival and mortality in prostate cancer treated with noncuratlve intent
19. Long-term survival among men with conservatively treated localized prostate cancer
20. Radical perineal prostatectomy: Oncological outcome during a 20-year period
21. Natural history of progression after PSA elevation following radical prostatectomy
22. Results of conservative management of clinically localized prostate cancer
23. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer
24. Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer
25. Prostate specific antigen after external beam radiotherapy for prostatic cancer: Follow up
26. Consensus statement: Guidelines for PSA following radiation therapy
27. Prostate cancer is highly predictable: A prognostic equation based on all morphological variables in radical prostatectomy specimens
28. La prostatectomie radicale: Résultats et perspectives
29. Staging prostate cancer, 1997: Current methods and limitations
30. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up
31. Predictors of virulence and selection of therapy for prostate cancer
32. + adenocarcinoma of prosrate treated with radical prosrarectomy and early androgen ablation
33. Adenocarcinoma of the prostate invading the seminal vesicle: Definition and relation of rumor volume, grade and margins of resection to prognosis
34. Advances in the assessment of clinically localized prostate cancer
35. Recurrence following radical surgery for prostatic cancer: Analysis of clinical, biological and anatomo-pathological prognostic factors
36. Distinguishing clinically important from unimportant prostate cancers before treatment: Value of systematic biopsies
37. Prediction of capsular perforation and seminal vesicle invasion in prostate cancer
38. The accuracy of diagnostic biopsy specimens in predicting tumor grades by Gleason's classification of radical prostatectomy specimens
39. Serum PSA after anatomic radical prostatectomy: The Johns Hopkins experience after 10 years
40. Detection of clinically significant prostate cancer by transrectal ultrasound-guided systematic biopsies
41. Prognostic value of a positive single ultrasound-guided prostatic biopsy regarding tumor volume and intracapsular nature of prostatic adenocarcinoma
42. The prognostic importance of Gleason grade in prostatic adenocarcinoma: A long-term follow-up study of 648 patients treated with radiation therapy
43. Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: Long-term results
44. Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of follow up
45. Disease progression following radical prostatectomy in men with Gleason score 7 tumor
46. Use of prostate-specific antigen, Gleason score, and digital rectal examination in staging patients with newly diagnosed prostate cancer
47. Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer
48. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy
49. Prognostic factors for clinically localized prostate carcinoma: Analysis of 938 patients irradiated in the prostate specific antigen era
50. Prognostic significance of prostate-specific antigen in stage Tlc prostate cancer treated by radical prostatectomy
51. Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis
52. Role of prostate-specific antigen velocity in prediction of final pathologic stage in men with localized prostate cancer
53. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer
54. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer
55. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer
56. Limitations of serum prostate specific antigen in predicting peripheral and transition zone cancer volumes as measured by correlation coefficients
57. Influence of noncancerous prostatic tissue volume on prostate-specific antigen
58. The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer
59. An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level
60. The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer
61. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update
62. Prostate specific antigen density as a prognostic factor for patients with prostate carcinoma treated with radiotherapy
63. Prostate-specific antigen cancer volume: A significant prognostic factor in prostate cancer patients at intermediate risk of failing radiotherapy
64. Predictive value of prostate-specific antigen density for the presence of micrometastatic carcinoma of the prostate
65. Utilité de l'antigène prostatique spécifique pour prédire la présence de métastases ganglionnaires dans le cancer de la prostate
66. Current prognostic factors for prostate carcinoma
67. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer
68. Influence of capsular penetration on progression following radical prostatectomy: A study of 196 cases with long-term follow up
69. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer
70. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer
71. Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer
72. Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathological stage in 275 patients with clinically localized adenocarcinoma of the prostate
73. Prognostic markers in clinically localized prostate cancer
74. A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma
75. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma
76. Future benefits and cost-effectiveness of prostate carcinoma screening
77. The impact of co-morbidity on life expectancy among men with localized prostate cancer
78. Co-morbidities and survival of men with localized prostate cancer treated with surgery or radiation therapy
79. Quantifying comorbidity in a disease-specific cohort: Adaptation of the total illness burden index to prostate cancer
80. Diagnosis of cancer of the prostate (I): Advancements in knowledge and practice since the consensus conference of 1989
81. When is a death from prostate cancer not a death from prostate cancer?
82. A comparison of cause of death determination in men previously diagnosed with prostate cancer who died in 1985 or 1995
83. Re: The impact of co-morbidity on life expectancy among men with localized prostate cancer
84. Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort
85. Comparing treatments for localized prostate cancer-persisting uncertainty
86. Comorbidity in patients with prostate cancer and its relevance to treatment choice
87. Why do sicker patients cost more? A charge-based analysis of patients undergoing prostatectomy
88. New classification of physical status
89. Are we selecting the right patients for treatment of localized prostate cancer? Results of an actuarial analysis
90. Cause of death in men diagnosed with prostate carcinoma
91. Impact of competing mortality on the cancer-related mortality in localized prostate cancer
92. Competing risks of mortality in prostate cancer
93. Performance status and comorbidity in elderly cancer patients compared with young patients with neoplasia and elderly patients without neoplastic conditions
94. La morbidité compétitive et son impact sur l'espérance de vie: Évaluation et prise en compte dans la décision thérapeutique du cancer localisé de la prostate